Trevi Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 10, 2022 at 09:12 pm
Share
Trevi Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 8.27 million compared to USD 7.26 million a year ago. Basic loss per share from continuing operations was USD 0.12 compared to USD 0.34 a year ago.
For the nine months, net loss was USD 23.65 million compared to USD 25.42 million a year ago. Basic loss per share from continuing operations was USD 0.44 compared to USD 1.25 a year ago.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Companyâs Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Companyâs subsidiary is Trevi Therapeutics Limited.